UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934
For the Month of April
Commission File Number 000-50994
BioProgress PLC
(Translation of registrant’s name into English)
15-17 Cambridge Science Park
Milton Road, Cambridge CB4 0FQ
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F X Form 40-F
Indicate by check mark whether registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):N/A
.
For Immediate Release 4 April 2007
BioProgress plc
Board Update
London, UK, 4 April 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM:
BPRG; NASDAQ: BPRG), the specialty pharmaceutical and healthcare company, is
pleased to announce the following reorganisation of its board. Anthony (Tony)
Knight, currently non-executive director, will take up the role of Non-Executive
Chairman whilst Peter Ibbetson, currently Non-Executive Chairman, will take up
the new role of Senior Non-Executive Independent Director. These board changes
are with immediate effect and reflect the Company's next phase of development.
Tony joined the Board in November 2005 as part of a continuing process of
evolving the competencies of the Board to anticipate the changing dynamics and
growing needs of the business. The past two years have been a time of constant
and necessary change for BioProgress plc. The Board has been led during this
period by Peter Ibbetson who, with the support of the rest of his colleagues,
has helped the CEO, Richard Trevillion, achieve the first phases of his vision
for the Company. During this period the Company has been transformed from a
general industrial technology platform business to a dynamic, international,
technology enabled, specialty pharmaceutical and healthcare business.
The next phase will be equally demanding for what is now a vibrant, growing
healthcare business. Peter has elected to take up the new board position of
Senior Non-Executive Independent Director. In recognition of the focus of the
business moving forward his position as Non-Executive Chairman will be taken up
by the pharmaceutical sales and market veteran Anthony Knight. The Directors
wish to record their grateful thanks for the contribution that Peter made during
his period as Chairman and look forward to working with him in his new role.
Anthony has over 30 years of experience in the Pharmaceutical Industry holding
senior positions in Marketing, Sales, Commercial, Training, Business Development
and Business Information as well as being chairman of the UK and Ireland
Pfizer/Warner Lambert co-promote venture. He left the board of Parke-Davis UK in
2000, where he was the Customer Marketing Director, following the take-over by
Pfizer during which time he was a senior member of the integration team. He then
established Portland Partnership with its primary focus of providing consultancy
services for Business Strategy in the Healthcare Sector challenging existing
business models and developing alternative solutions. He has collaborated with
University departments on his novel outcomes guarantee methodology and is a
contributor to INSEAD's Healthcare 2020 forum.
Richard Trevillion, Chief Executive Officer, said:
"As the Company enters its next stages of development and growth, market
positioning and marketing strategy will be of increasing importance. Tony's
background and network will be of tremendous value in achieving our goals and
I'm delighted he has agreed to move up to the role of Chairman. I would like to
record our thanks to Peter for his contribution as Non-Executive Chairman over
the past 18 months, a period of significant re-organisation for the Company, and
look forward to continuing to work with Peter in his new role."
Anthony Knight, Non - Executive Chairman, said:
"I feel privileged to have been elected to the Chair by my colleagues. I look
forward to providing focussed leadership to the Board to help the executive team
drive the business forward to achieve its goals and in so doing create
substantial and sustainable value for our shareholders."
Peter Ibbetson, Senior Non-Executive Director, said:
"It has been a privilege to work with the Board during the restructuring of the
Company, and as we look to the next stage of development I am delighted that
Tony has agreed to take the lead leveraging his extensive experience."
For further information:
BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO
Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich
Mark Court
About BioProgress
BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company
has over 80 patents granted or in application within 24 patent families and has
product development agreements and strategic alliances with several global
companies. As a virtually integrated business, BioProgress has acquired sales
and marketing resources within Europe and the US as a launch mechanism for its
own pharmaceutical products. The business continues to develop innovative
delivery mechanisms using its XGEL™ polymer technology, replacing the need
to use animal-derived gelatine in pharmaceutical and healthcare products. For
further information please go to www.bioprogress.com
Forward-Looking Information
The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies. These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances. Actual results may vary materially from the
expectations contained in the forward-looking statements. The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation. Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company's filings with the
Securities and Exchange Commission. The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice. The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law. Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.
END
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.